The stock has a 36-month beta value of 1.52. Opinions on the stock are mixed, with 1 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for CUE is 74.78M, and at present, short sellers hold a 1.11% of that float. On July 04, 2025, the average trading volume of CUE was 225.53K shares.
CUE stock’s latest price update
Cue Biopharma Inc (NASDAQ: CUE)’s stock price has soared by 0.46% in relation to previous closing price of $0.69. Nevertheless, the company has seen a loss of -11.93% in its stock price over the last five trading days. globenewswire.com reported 2025-07-01 that ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC 12-month landmark survival of 88% and mOS of 32 months
CUE’s Market Performance
Cue Biopharma Inc (CUE) has seen a -11.93% fall in stock performance for the week, with a 10.05% gain in the past month and a -12.01% plunge in the past quarter. The volatility ratio for the week is 8.17%, and the volatility levels for the past 30 days are at 10.43% for CUE. The simple moving average for the past 20 days is 3.91% for CUE’s stock, with a -32.73% simple moving average for the past 200 days.
Analysts’ Opinion of CUE
Many brokerage firms have already submitted their reports for CUE stocks, with Jefferies repeating the rating for CUE by listing it as a “Buy”. The predicted price for CUE in the upcoming period, according to Jefferies is $6 based on the research report published on March 13, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CUE reach a price target of $10. The rating they have provided for CUE stocks is “Outperform” according to the report published on June 26th, 2023.
H.C. Wainwright gave a rating of “Buy” to CUE, setting the target price at $20 in the report published on January 13th of the previous year.
CUE Trading at -0.85% from the 50-Day Moving Average
After a stumble in the market that brought CUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.05% of loss for the given period.
Volatility was left at 10.43%, however, over the last 30 days, the volatility rate increased by 8.17%, as shares surge +12.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.18% lower at present.
During the last 5 trading sessions, CUE fell by -11.93%, which changed the moving average for the period of 200-days by +18.03% in comparison to the 20-day moving average, which settled at $0.6693. In addition, Cue Biopharma Inc saw -31.84% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CUE starting from PASSERI DANIEL R, who purchase 30,000 shares at the price of $1.03 back on Dec 16 ’24. After this action, PASSERI DANIEL R now owns 164,578 shares of Cue Biopharma Inc, valued at $30,900 using the latest closing price.
N/A, the N/A of Cue Biopharma Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for CUE
Current profitability levels for the company are sitting at:
- -5.15% for the present operating margin
- -0.25% for the gross margin
The net margin for Cue Biopharma Inc stands at -5.08%. The total capital return value is set at -6.09%. Equity return is now at value -221.66%, with -106.51% for asset returns.
Based on Cue Biopharma Inc (CUE), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -4.87. The debt to equity ratio resting at 1.08. The interest coverage ratio of the stock is -96.1.
Currently, EBITDA for the company is -37.53 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 5.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
To sum up, Cue Biopharma Inc (CUE) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
